Patterns of Somatic Variants in Colorectal Adenoma and Carcinoma Tissue and Matched Plasma Samples from the Hungarian Oncogenome Program.
Alexandra KalmárOrsolya GalambGitta SzabóOrsolya Anna PipekAnna Medgyes-HorváthBarbara K BartákZsófia B NagyKrisztina A SzigetiSára ZsigraiIstván CsabaiPéter IgazBéla MolnárIstván TakácsPublished in: Cancers (2023)
Analysis of circulating cell-free DNA (cfDNA) of colorectal adenoma (AD) and cancer (CRC) patients provides a minimally invasive approach that is able to explore genetic alterations. It is unknown whether there are specific genetic variants that could explain the high prevalence of CRC in Hungary. Whole-exome sequencing (WES) was performed on colon tissues (27 AD, 51 CRC) and matched cfDNAs (17 AD, 33 CRC); furthermore, targeted panel sequencing was performed on a subset of cfDNA samples. The most frequently mutated genes were APC , KRAS , and FBN3 in AD, while APC , TP53 , TTN , and KRAS were the most frequently mutated in CRC tissue. Variants in KRAS codons 12 (AD: 8/27, CRC: 11/51 (0.216)) and 13 (CRC: 3/51 (0.06)) were the most frequent in our sample set, with G12V (5/27) dominance in ADs and G12D (5/51 (0.098)) in CRCs. In terms of the cfDNA WES results, tumor somatic variants were found in 6/33 of CRC cases. Panel sequencing revealed somatic variants in 8 out of the 12 enrolled patients, identifying 12/20 tumor somatic variants falling on its targeted regions, while WES recovered only 20% in the respective regions in cfDNA of the same patients. In liquid biopsy analyses, WES is less efficient compared to the targeted panel sequencing with a higher coverage depth that can hold a relevant clinical potential to be applied in everyday practice in the future.
Keyphrases
- copy number
- end stage renal disease
- chronic kidney disease
- ejection fraction
- minimally invasive
- newly diagnosed
- prognostic factors
- healthcare
- single cell
- peritoneal dialysis
- squamous cell carcinoma
- cancer therapy
- primary care
- drug delivery
- risk assessment
- current status
- health insurance
- optical coherence tomography
- human health
- squamous cell